Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

计划入组 600 人 · 首次发布于 2026 年 3 月 9 日

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

计划入组 300 人 · 首次发布于 2025 年 11 月 24 日

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

计划入组 300 人 · 首次发布于 2026 年 6 月 10 日

VP-100

Cantharidin(Cantharone Plus, Ycanth)

C₁₀H₁₂O₄ · Rx

VP-003

EdiGene Inc.

China

NIPPON MEDICAL SCHOOL

Japan

Lederle Laboratories

United States

Verrica to Present VP-315 Immune Activation Data from Phase 2 Basal Cell Carcinoma Trial at SITC 2025

Verrica Pharmaceuticals Launches Global Phase 3 Trial for YCANTH in Common Warts, Targeting 22 Million US Patients

Verrica Doses First U.S. and Japanese Patients in Phase 3 COVE-3 Trial of YCANTH for Common Warts